Travere Therapeutics, Inc. Research And Development Expense

Quick Answer

Travere Therapeutics, Inc. reported Research And Development Expense of $140.96 million for the year ending 2019.

  • Travere Therapeutics, Inc. showed an increase of +13.9% in Research And Development Expense from 2018 to 2019.
  • This data is from Travere Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2020.
  • XBRL data for this metric is available from 2012 to 2019 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 8 years of available data (2012 to 2019), Travere Therapeutics, Inc.'s Research And Development Expense has grown by 21,177.4%.
  • Historical annual values: Fiscal year 2019: $140.96 million | Fiscal year 2018: $123.76 million | Fiscal year 2017: $78.17 million | Fiscal year 2016: $70.82 million | Fiscal year 2015: $50.43 million | Fiscal year 2014: $47.80 million | Fiscal year 2013: $7.08 million | Fiscal year 2012: $662.5 thousand.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: